PMS-SITAGLIPTIN TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE)

থেকে পাওয়া:

PHARMASCIENCE INC

এটিসি কোড:

A10BH01

INN (আন্তর্জাতিক নাম):

SITAGLIPTIN

ডোজ:

100MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0152414001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2023-01-05

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-SITAGLIPTIN
Sitagliptin Tablets
Tablets, 25, 50 and 100 mg sitagliptin (as sitagliptin phosphate
monohydrate) Oral
House Standard
Dipeptidyl peptidase 4 (DPP-4) inhibitors
PHARMASCIENCE INC
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
Date of Initial Authorization:
August 18, 2020
Date of Revision:
December 14, 2021
www.pharmascience.com
Submission Control Number: 254974
_pms-SITAGLIPTIN (sitagliptin) Page 2 of 56 _
RECENT MAJOR LABEL CHANGES
1 Indications
12/2021
4 Dosage and Administration
12/2021
7 Warnings and Precautions
12/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................................4
1
INDICATIONS
....................................................................................................................4
1.1 Pediatrics
....................................................................................................................4
1.2 Geriatrics
....................................................................................................................4
2
CONTRAINDICATIONS
........................................................................................................4
4
DOSAGE AND ADMINISTRATION
.........................................................................................4
4.1 Dosing
Considerations...................................................................................................4
4.2 Recommended Dose and Dosage
Adjustment...................................................................5
4.4 Administration
.............................................................................................................5
4.5 Missed Dose
................................................................................................................6
5
OVERDOSAGE
............................................